This study is for people with newly diagnosed multiple myeloma, a type of blood cancer. It tests the effectiveness of two different medicine combinations: Teclistamab, Daratumumab, and Lenalidomide (Tec-DR), and Talquetamab, Daratumumab, and Lenalidomide (Tal-DR). These will be compared to a standard treatment using Daratumumab, Lenalidomide, and Dexamethasone (DRd). Participants cannot have had previous treatments for multiple myeloma and must not be suited for high-dose chemotherapy or a stem cell transplant due to age or other health issues. They must not be pregnant or plan to have children during and after the study for a specific time.

• Participants need to have a good health score and agree to certain lifestyle precautions.
• The study excludes those having had recent treatments or other health issues like strokes or allergies to study drugs.
• No previous therapy for multiple myeloma is allowed, except some corticosteroid use.